Advertisement

PentaVision

Glaucoma Physician

Article | 2026 American Glaucoma Society Meeting

Video: Novel Vasodilator Targets Distal Outflow

At AGS 2026, Barbara Wirostko, MD, FARVO, reviewed top-line data on QLS-111, including additive IOP lowering on latanoprost.

By: Barbara M. Wirostko, MD, FARVO
Glaucoma Physician February 21, 2026

Clinical Scorecard: Novel Vasodilator Targets Distal Outflow in Glaucoma Management

At a Glance

CategoryDetail
ConditionGlaucoma with elevated intraocular pressure (IOP)
Key MechanismsVasodilation of distal outflow system beyond trabecular meshwork; potential improvement of optic nerve head perfusion
Target PopulationPatients with glaucoma requiring additional IOP lowering beyond standard therapy
Care SettingOphthalmology outpatient clinics and glaucoma specialty care

Key Highlights

  • QLS-111 is a novel vasodilatory agent targeting distal aqueous outflow pathways to reduce IOP.
  • Additive IOP reduction of approximately 3.2 to 3.6 mmHg achieved when QLS-111 is added to latanoprost therapy.
  • Once-daily, preservative-free, isotonic, and pH-neutral formulation demonstrates an excellent safety profile.

Guideline-Based Recommendations

Diagnosis

  • Identify patients with glaucoma inadequately controlled on current IOP-lowering therapies.

Management

  • Consider adding QLS-111 to existing latanoprost regimen to achieve additional IOP reduction.
  • Utilize once-daily PM dosing of QLS-111 based on optimal concentration findings.

Monitoring & Follow-up

  • Monitor IOP response and optic nerve head perfusion during combination therapy.
  • Assess for any adverse effects given the favorable safety profile.

Risks

  • No significant safety concerns reported with preservative-free, isotonic, pH-neutral QLS-111 formulation.

Patient & Prescribing Data

Glaucoma patients currently treated with latanoprost requiring further IOP lowering

QLS-111 provides additive IOP lowering (~3.2-3.6 mmHg) when combined with latanoprost, supporting its use as adjunctive therapy.

Clinical Best Practices

  • Start with standard IOP-lowering agents such as latanoprost before adding novel agents like QLS-111.
  • Use once-daily evening dosing of QLS-111 to optimize patient adherence and efficacy.
  • Select preservative-free formulations to minimize ocular surface toxicity.
  • Consider fixed-dose combination therapies to simplify regimens and improve compliance.

References